Serum proteomics analysis and comparisons using iTRAQ in the progression of hepatitis B

Peng,Liang; Liu,Jing; Li,Yang‑Mei; Huang,Zhan‑Lian; Wang,Pei‑Pei; Gu,Yu‑Rong; Zheng,Yu‑Bao; Gao,Zhi‑Liang

doi:10.3892/etm.2013.1310

Serum proteomics analysis and comparisons using iTRAQ in the progression of hepatitis B

Authors:
- Liang Peng
- Jing Liu
- Yang‑Mei Li
- Zhan‑Lian Huang
- Pei‑Pei Wang
- Yu‑Rong Gu
- Yu‑Bao Zheng
- Zhi‑Liang Gao
View Affiliations

Affiliations: Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510630, P.R. China, Department of Traditional Chinese Medicine, Third Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510630, P.R. China
Published online on: September 18, 2013 https://doi.org/10.3892/etm.2013.1310
Pages: 1169-1176

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to analyze the changes in serum protein levels in the progression of hepatitis B using isobaric tags for relative and absolute quantitation (iTRAQ) analysis, in addition to comparing the serum protein levels of patients with chronic hepatitis B (CHB), patients with hepatitis B virus‑induced acute‑on‑chronic liver failure (HBV‑induced ACLF) and normal individuals. Protein analysis was performed on 15 serum samples using iTRAQ. The study population included healthy controls (n=5), patients with CHB (n=5) and patients with HBV‑induced ACLF (n=5). Western blotting was used to verify the results in an additional nine serum samples from healthy controls, patients with CHB and patients with HBV‑induced ACLF (n=3, respectively). Using iTRAQ analysis, 16 different serum proteins with ≥1.5‑fold differences in expression levels were identified in the patients with CHB and ACLF compared with the healthy controls. Five of those proteins, C‑reactive protein precursor, hemoglobin β chain variant Hb S‑Wake, apolipoprotein J precursor, platelet factor 4 precursor and vitronectin, which demonstrated the greatest differences in their expression levels and the most significant correlation with liver diseases, were subsequently verified using western blotting. The western blotting results were consistent with the results from the iTRAQ. Two of the five proteins are not classified by biological process, and the biological functions of all the proteins in HBV‑induced ACLF remain unclear. This preliminary study demonstrated that a correlation between the expression of various serum proteins and the different pathogenetic conditions induced by HBV may exist. The analysis of a larger number of samples is required to identify potential protein biomarkers that may be involved in the pathogenesis and progression of hepatitis B.

View Figures

View References

1.	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association: The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi. 19:13–24. 201l.(In Chinese).
2.	Lu FM and Zhuang H: Management of hepatitis B in China. Chin Med J (Engl). 122:3–4. 2009.
3.	Ren F, Chen Y, Wang Y, Yan Y, Zhao J, Ding M, Zhang J, Jiang Y, Zhai Y and Duan Z: Comparative serum proteomic analysis of patients with acute-on-chronic liver failure: alpha-1-acid glycoprotein maybe a candidate marker for prognosis of hepatitis B virus infection. J Viral Hepat. 17:816–824. 2010. View Article : Google Scholar : PubMed/NCBI
4.	Yang L, Rudser KD, Higgins L, Rosen HR, Zaman A, Corless CL, David L and Gourley GR: Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics. Dig Dis Sci. 56:3305–3315. 2011. View Article : Google Scholar : PubMed/NCBI
5.	Jin GZ, Li Y, Cong WM, Yu H, Dong H, Shu H, Liu XH, Yan GQ, Zhang L, Zhang Y, et al: iTRAQ-2DLC-ESI-MS/MS based identification of a new set of immunohistochemical biomarkers for classification of dysplastic nodules and small hepatocellular carcinoma. J Proteome Res. 10:3418–3428. 2011. View Article : Google Scholar : PubMed/NCBI
6.	Lee HJ, Na K, Choi EY, Kim KS, Kim H and Paik YK: Simple method for quantitative analysis of N-linked glycoproteins in hepatocellular carcinoma specimens. J Proteome Res. 9:308–318. 2010. View Article : Google Scholar : PubMed/NCBI
7.	Goh WW, Lee YH, Zubaidah RM, Jin J, Dong D, Lin Q, Chung MC and Wong L: Network-based pipeline for analyzing MS data: an application toward liver cancer. J Proteome Res. 10:2261–2272. 2011. View Article : Google Scholar : PubMed/NCBI
8.	Wu WW, Wang G, Baek SJ and Shen RF: Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J Proteome Res. 5:651–658. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Kolla V, Jenö P, Moes S, Tercanli S, Lapaire O, Choolani M and Hahn S: Quantitative proteomics analysis of maternal plasma in Down syndrome pregnancies using isobaric tagging reagent (iTRAQ). J Biomed Biotechnol. 2010:9520472010. View Article : Google Scholar : PubMed/NCBI
10.	Lok AS and McMahon BJ: Chronic hepatitis B: update 2009. Hepatology. 50:661–662. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, et al: Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int. 3:269–282. 2009. View Article : Google Scholar
12.	Nahum E, Livni G, Schiller O, Bitan S, Ashkenazi S and Dagan O: Role of C-reactive protein velocity in the diagnosis of early bacterial infections in children after cardiac surgery. J Intensive Care Med. 27:191–196. 2012. View Article : Google Scholar : PubMed/NCBI
13.	Sklavou R, Karavanaki K, Critselis E, Kossiva L, Giannaki M, Tsolia M, Papadakis V, Papargyri S, Vlachou A, Karantonis F, Gourgiotis D and Polychronopoulou S: Variation of serum C-reactive protein (CRP) over time in pediatric cancer patients with febrile illness and its relevance to identified pathogen. Clin Biochem. 45:1178–1182. 2012. View Article : Google Scholar : PubMed/NCBI
14.	Kashiwagi M, Tanaka A, Kitabata H, Tsujioka H, Matsumoto H, Arita Y, Ookochi K, Kuroi A, Kataiwa H, Tanimoto T, et al: Relationship between coronary arterial remodeling, fibrous cap thickness and high-sensitivity C-reactive protein levels in patients with acute coronary syndrome. Circ J. 73:1291–1295. 2009. View Article : Google Scholar
15.	Kutlar F, Redding-Lallinger R, Meiler SE, Bakanay SM, Borders L and Kutlar A: A new sickling variant ‘Hb S-Wake β [(Glu6Val-Asn139 Ser)]’ found in a compound heterozygote with Hb S β (Glu6Val) coinherited with homozygous α-thalassemia-2: phenotype and molecular characteristics. Acta Haematol. 124:120–124. 2010.
16.	Trougakos IP and Gonos ES: Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol. 34:1430–1448. 2002. View Article : Google Scholar : PubMed/NCBI
17.	Gangadharan B, Bapat M, Rossa J, Antrobus R, Chittenden D, Kampa B, Barnes E, Klenerman P, Dwek RA and Zitzmann N: Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study. PLoS One. 7:e396032012. View Article : Google Scholar
18.	Poon TC, Pang RT, Chan KC, Lee NL, Chiu RW, Tong YK, Chim SS, Ngai SM, Sung JJ and Lo YM: Proteomic analysis reveals platelet factor 4 and beta-thromboglobulin as prognostic markers in severe acute respiratory syndrome. Electrophoresis. 33:1894–1900. 2012. View Article : Google Scholar : PubMed/NCBI
19.	Panasiuk A, Prokopowicz D, Zak J, Matowicka-Karna J, Osada J and Wysocka J: Activation of blood platelets in chronic hepatitis and liver cirrhosis P-selectin expression on blood platelets and secretory activity of beta-thromboglobulin and platelet factor-4. Hepatogastroenterology. 48:818–822. 2001.PubMed/NCBI
20.	Sano K, Asanuma-Date K, Arisaka F, Hattori S and Ogawa H: Changes in glycosylation of vitronectin modulate multimerization and collagen binding during liver regeneration. Glycobiology. 17:784–794. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Sano K, Miyamoto Y, Kawasaki N, Hashii N, Itoh S, Murase M, Date K, Yokoyama M, Sato C, Kitajima K and Ogawa H: Survival signals of hepatic stellate cells in liver regeneration are regulated by glycosylation changes in rat vitronectin, especially decreased sialylation. J Biol Chem. 285:17301–17309. 2010. View Article : Google Scholar
22.	Koukoulis GK, Shen J, Virtanen I and Gould VE: Vitronectin in the cirrhotic liver: an immunomarker of mature fibrosis. Hum Pathol. 32:1356–1362. 2001. View Article : Google Scholar : PubMed/NCBI
23.	Yamada S, Kobayashi J, Murawaki Y, Suou T and Kawasaki H: Collagen-binding activity of plasma vitronectin in chronic liver disease. Clin Chim Acta. 252:95–103. 1996. View Article : Google Scholar : PubMed/NCBI
24.	Kobayashi J, Yamada S and Kawasaki H: Distribution of vitronectin in plasma and liver tissue: relationship to chronic liver disease. Hepatology. 20:1412–1417. 1994. View Article : Google Scholar : PubMed/NCBI
25.	Tomihira M: Changes in plasma vitronectin, fibronectin, and serum laminin P1 levels and immunohistochemical study of vitronectin in the liver of patients with chronic liver diseases. Fukuoka Igaku Zasshi. 82:21–30. 1991.(In Japanese).